The competition brought together nine pioneering startups innovating across fertility and women’s health, including Conceivable Life Sciences, Betterfit, Biotech Inc., Fertilis, NeoGenix, OWLO, Somos Ovum, Verso Biosense, and U-Ploid Biotechnologies. Judges highlighted the consistently high calibre of science and engineering across the cohort.
U-Ploid received the award in recognition of its lead investigational product Lyvanta™, a first-in-class therapy designed to restore oocyte chromosomal stability in women of advanced maternal age. Alexandre Webster, Co-Founder and Chief Scientific Officer, presented new mechanistic and translational data supporting Lyvanta’s development to an international panel of experts.
“The Carlos Simón Foundation convenes many of the field’s most forward-thinking scientists and clinicians,” added Dr. Webster. “It was a privilege to present Lyvanta among such strong peers, and we are grateful for the recognition.”
U-Ploid will continue driving translational research that brings cutting-edge reproductive biology closer to clinical impact.
About U-Ploid Biotechnologies
U-Ploid is a biotechnology company developing next-generation fertility therapeutics to address the global challenge of age-related infertility. Co-founded by Jordan Abdi, Chloe Charalambous, and Alexandre Webster, U-Ploid is pioneering innovative solutions to improve IVF outcomes and expand the window of reproductive opportunity. The company's technology is designed to increase the quality of older eggs, restoring their potential to support healthy pregnancies. U-Ploid is committed to improving access to fertility care and envisions a future where anyone who wants to start a family, can. For more information, go to u-ploid.com or follow us on LinkedIn.